Establishment Labs (NASDAQ:ESTA) Shares Down 5.3%

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) dropped 5.3% on Friday . The stock traded as low as $49.28 and last traded at $49.80. Approximately 126,477 shares traded hands during trading, a decline of 70% from the average daily volume of 428,203 shares. The stock had previously closed at $52.57.

Analyst Ratings Changes

ESTA has been the subject of several analyst reports. Citigroup increased their target price on Establishment Labs from $49.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. JPMorgan Chase & Co. increased their target price on Establishment Labs from $46.00 to $53.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. Mizuho increased their target price on Establishment Labs from $50.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Finally, Stephens reissued an “overweight” rating and issued a $47.00 target price on shares of Establishment Labs in a research report on Thursday, January 11th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Establishment Labs presently has an average rating of “Buy” and an average target price of $55.00.

Establishment Labs Price Performance

The stock has a market cap of $1.30 billion, a P/E ratio of -15.59 and a beta of 1.24. The firm has a 50-day moving average price of $47.12 and a 200-day moving average price of $36.32. The company has a debt-to-equity ratio of 10.26, a quick ratio of 1.67 and a current ratio of 3.06.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.16. Establishment Labs had a negative return on equity of 357.81% and a negative net margin of 47.53%. The company had revenue of $31.60 million during the quarter, compared to analyst estimates of $31.44 million. During the same quarter last year, the company earned ($0.55) EPS. The firm’s revenue for the quarter was down 27.9% on a year-over-year basis. On average, analysts forecast that Establishment Labs Holdings Inc. will post -1.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JW Asset Management LLC increased its position in Establishment Labs by 0.8% during the 1st quarter. JW Asset Management LLC now owns 3,142,485 shares of the company’s stock valued at $211,772,000 after buying an additional 25,000 shares in the last quarter. Brown Advisory Inc. increased its position in Establishment Labs by 63.9% during the 4th quarter. Brown Advisory Inc. now owns 2,428,792 shares of the company’s stock valued at $62,881,000 after buying an additional 946,612 shares in the last quarter. Nantahala Capital Management LLC increased its position in Establishment Labs by 1.2% during the 1st quarter. Nantahala Capital Management LLC now owns 2,149,201 shares of the company’s stock valued at $144,835,000 after buying an additional 25,965 shares in the last quarter. Cowen AND Company LLC boosted its stake in Establishment Labs by 18.1% during the 3rd quarter. Cowen AND Company LLC now owns 1,141,172 shares of the company’s stock valued at $55,997,000 after purchasing an additional 175,000 shares during the last quarter. Finally, Findell Capital Management LLC purchased a new stake in Establishment Labs during the 4th quarter valued at $14,680,000. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.